Webb, EJD; Meads, DM; Eskyte, I; Ford, HL; Bekker, HL; Chataway, J; Pepper, G; ... Manzano, A; + view all Webb, EJD; Meads, DM; Eskyte, I; Ford, HL; Bekker, HL; Chataway, J; Pepper, G; Marti, J; Okan, Y; Pavitt, SH; Schmierer, K; Manzano, A; - view fewer (2020) The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments. The Patient - Patient-Centered Outcomes Research , 13 (5) pp. 583-597. 10.1007/s40271-020-00429-4.

Preview

Text Chataway_EWebb_Reproduction_paper_2nd_revision_final.pdf - Accepted Version Download (587kB) | Preview

Abstract

Background: Relapsing–remitting multiple sclerosis (RRMS) is an incurable disease characterised by relapses (periods of function loss) followed by full or partial recovery, and potential permanent disability over time. Many disease-modifying treatments (DMTs) exist that help reduce relapses and slow disease progression. Most are contraindicated during conception/pregnancy and some require a discontinuation period before trying to conceive. Although around three-quarters of people with RRMS are women, there is limited knowledge about how reproductive issues impact DMT preference. Objective: The aim of this study was to measure the preferences for DMTs of women with RRMS who are considering pregnancy. Design: An online discrete choice experiment (DCE). Methods: Participants chose between two hypothetical DMTs characterised by a set of attributes, then indicated if they preferred their choice to no treatment. Attributes were identified from interviews and focus groups with people with RRMS and MS professionals, as well as literature reviews, and included the probability of problems with pregnancy, discontinuation of DMTs, and breastfeeding safety. In each DCE task, participants were asked to imagine making decisions in three scenarios: now; when trying to conceive; and when pregnant. Analysis: Two mixed logit models were estimated, one to assess the statistical significance between scenarios and one in maximum acceptable risk space to allow comparison of the magnitudes of parameters between scenarios. Sample: Women with RRMS who were considering having a child in the future, recruited from a UK MS patient register. Results: Sixty respondents completed the survey. Participants preferred no treatment in 12.6% of choices in the ‘now’ scenario, rising significantly to 37.6% in the ‘trying to conceive’ scenario and 60.3% in the ‘pregnant’ scenario (Kruskal–Wallis p < 0.001). This pattern corresponds with results from models that included a no-treatment alternative-specific constant (ASC) capturing differences between taking and not taking a DMT not specified by the attributes. The ASC was lower in the trying to conceive scenario than in the now scenario, and lower still in the pregnant scenario, indicating an intrinsic preference for no treatment. Participants also placed relatively less preference on reducing relapses and avoiding disease progression in the trying to conceive and pregnant scenarios compared with a lower risk of problems with pregnancy. In the trying to conceive scenario, participants’ preference for treatments with shorter washout periods increased. Conclusion: Women with RRMS considering having a child prefer DMTs with more favourable reproduction-related attributes, even when not trying to conceive. Reproductive issues also influenced preferences for DMT attributes not directly related to pregnancy, with preferences dependent on the life circumstances in which choices were made. The design of the DCE highlights the benefits of considering the scenario in which participants make choices, as they may change over time.

Download activity - last month

Export as XMLCSVJSON

Download activity - last 12 months

Export as JSONXMLCSV

Downloads by country - last 12 months

Export as JSONXMLCSV

Archive Staff Only

View Item